WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994025462) 8-SUBSTITUTED 1,3,7-TRIALKYL-XANTHINE DERIVATIVES AS A2-SELECTIVE ADENOSINE RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/025462    International Application No.:    PCT/US1994/004876
Publication Date: 10.11.1994 International Filing Date: 03.05.1994
Chapter 2 Demand Filed:    28.11.1994    
IPC:
C07D 473/06 (2006.01), C07D 473/10 (2006.01), C07D 473/12 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, represented by THE [US/US]; SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, Office of Technology Transfer, Box OTT, Bethesda, MD 20892-9902 (US)
Inventors: JACOBSON, Kenneth, A.; (US).
KARTON, Yishai; (IL).
GALLO-RODRIGUEZ, Carola; (US).
FISCHER, Bilha; (US).
VAN GALEN, Philip, J., M.; (US).
MAILLARD, Michel; (US)
Agent: KILYK, John, Jr.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US)
Priority Data:
08/057,086 03.05.1993 US
Title (EN) 8-SUBSTITUTED 1,3,7-TRIALKYL-XANTHINE DERIVATIVES AS A2-SELECTIVE ADENOSINE RECEPTOR ANTAGONISTS
(FR) DERIVES DE 1,3,7-TRIALKYL-XANTHINE SUBSTITUES EN POSITION 8 UTILES COMME ANTAGONISTES DE RECEPTEURS D'ADENOSINE A¿2? A SELECTIVITE
Abstract: front page image
(EN)The present invention provides 8-substituted 1,3,7-trialkylxanthine derivatives, pharmaceutical compositions comprising such derivatives, and a method of using such derivatives as A¿2?-selective adenosine receptor antagonists in the treatment of a mammal, in particular a human, in need of selective antagonism of its A¿2?-adenosine receptors.
(FR)Cette invention concerne des dérivés de 1,3,7-trialkylxanthine substitués en position 8, des compositions pharmaceutiques comprenant ces dérivés, ainsi qu'un procédé d'utilisation de ces derniers en tant qu'antagonistes de récepteurs d'adénosine A¿2? à sélectivité dans le traitement d'un mammifère, notamment l'homme, nécessitant l'antagonisme sélectif de ses récepteurs d'adénosine A¿2?.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)